|
MechanismCEACAM5 antagonists |
|
|
|
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target- |
Mechanism- |
|
|
|
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
|
MechanismSMPD1 inhibitors |
Active Org.- |
|
Active Indication- |
|
Drug Highest PhasePending |
First Approval Ctry. / Loc.- |
First Approval Date- |
/ CompletedNot Applicable [Translation] Bioequivalence study of irbesartan tablets in humans after single fasting administration
研究健康受试者单次空腹口服厄贝沙坦片的血药浓度经时过程,估算相应的药代动力学参数,并以处方变更前产品(安博维)为标准参比制剂,进行生物等效性评价。
[Translation] The time course of blood drug concentration of irbesartan tablets after a single oral administration of fasting oral administration to healthy subjects was studied, the corresponding pharmacokinetic parameters were estimated, and the bioequivalence evaluation was performed using the product before the prescription change (Ambrovi) as the standard reference preparation.
100 Clinical Results associated with Sanofi (Hangzhou) Pharmaceuticals Co., Ltd.
0 Patents (Medical) associated with Sanofi (Hangzhou) Pharmaceuticals Co., Ltd.
100 Deals associated with Sanofi (Hangzhou) Pharmaceuticals Co., Ltd.
100 Translational Medicine associated with Sanofi (Hangzhou) Pharmaceuticals Co., Ltd.